Association of Pneumococcal Conjugate Vaccine Coverage With Pneumococcal Meningitis: An Analysis of French Administrative Areas, 2001-2016.
Bayesian inference
National Health Insurance data
administrative area variations
mixed-effect Poisson model
pneumococcal conjugate vaccine
pneumococcal meningitis
vaccine coverage
Journal
American journal of epidemiology
ISSN: 1476-6256
Titre abrégé: Am J Epidemiol
Pays: United States
ID NLM: 7910653
Informations de publication
Date de publication:
01 08 2019
01 08 2019
Historique:
received:
23
07
2018
revised:
08
03
2019
accepted:
12
03
2019
pubmed:
15
6
2019
medline:
21
3
2020
entrez:
15
6
2019
Statut:
ppublish
Résumé
Geographic variations of invasive pneumococcal disease incidence and serotype distributions were observed after pneumococcal conjugate vaccine introduction at regional levels and among French administrative areas. The variations could be related to regional vaccine coverage (VC) variations that might have direct consequences for vaccination-policy impact on invasive pneumococcal disease, particularly pneumococcal meningitis (PM) incidence. We assessed vaccine impact from 2001 to 2016 in France by estimating the contribution of regional VC differences to variations of annual local PM incidence. Using a mixed-effect Poisson model, we showed that, despite some variations of VC among administrative areas, vaccine impact on vaccine-serotype PM was homogeneously confirmed among administrative areas. Compared with the prevaccine era, the cumulative VC impact on vaccine serotypes led, in 2016, to PM reductions ranging among regions from 87% (25th percentile) to 91% (75th percentile) for 7-valent pneumococcal conjugate vaccine serotypes and from 58% to 63% for the 6 additional 13-valent pneumococcal conjugate vaccine serotypes. Nonvaccine-serotype PM increases from the prevaccine era ranged among areas from 98% to 127%. By taking into account the cumulative impact of growing VC and VC differences, our analyses confirmed high vaccine impact on vaccine-serotype PM case rates and suggest that VC variations cannot explain PM administrative area differences.
Identifiants
pubmed: 31197305
pii: 5421028
doi: 10.1093/aje/kwz071
pmc: PMC6670069
doi:
Substances chimiques
Heptavalent Pneumococcal Conjugate Vaccine
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1466-1474Informations de copyright
© The Author(s) 2019. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health.
Références
PLoS One. 2010 Feb 08;5(2):e9102
pubmed: 20161709
JAMA. 1995 Mar 15;273(11):859-64
pubmed: 7869556
Proc Biol Sci. 2013 Jun 19;280(1764):20130519
pubmed: 23782877
Epidemiol Infect. 2008 Aug;136(8):1096-102
pubmed: 17961282
Lancet. 1997 May 24;349(9064):1554
pubmed: 9167485
Infect Dis (Lond). 2017 Jun;49(6):433-444
pubmed: 28301990
J Infect. 2009 Jan;58(1):37-46
pubmed: 19042025
Pediatrics. 1999 Mar;103(3):E28
pubmed: 10049984
Lancet. 2001 Mar 24;357(9260):950-2
pubmed: 11289365
Clin Infect Dis. 2011 Jul 15;53(2):137-43
pubmed: 21690620
Eur J Pediatr. 2002 Apr;161(4):188-95
pubmed: 12014384
J Infect Dis. 2010 Oct 15;202(8):1287-95
pubmed: 20822454
Vaccine. 2017 Jul 5;35(31):3797-3800
pubmed: 28619234
Eur J Pediatr. 2002 Dec;161 Suppl 2:S135-9
pubmed: 12494260
Stat Med. 2018 Feb 20;37(4):572-589
pubmed: 29114926
Rev Epidemiol Sante Publique. 2017 Oct;65 Suppl 4:S149-S167
pubmed: 28756037
BMC Med. 2016 Dec 21;14(1):211
pubmed: 27998266
J Allergy Clin Immunol. 2017 Mar;139(3):977-986.e2
pubmed: 27523432
Lancet Infect Dis. 2006 Jul;6(7):405-10
pubmed: 16790381
Sci Rep. 2015 Jun 11;5:11293
pubmed: 26063589
BMC Public Health. 2016 May 13;16:400
pubmed: 27178436
Vaccine. 2015 Jan 3;33(2):359-66
pubmed: 25448105
Semin Respir Crit Care Med. 2009 Apr;30(2):189-209
pubmed: 19296419
Neth J Med. 2015 Feb;73(2):53-60
pubmed: 25753069
Pediatr Infect Dis J. 2017 May;36(5):457-461
pubmed: 28403047
PLoS Med. 2013;10(9):e1001517
pubmed: 24086113
Vaccine. 2013 Dec 17;32(1):133-45
pubmed: 23684824
Euro Surveill. 2006 Sep;11(9):171-8
pubmed: 17075159
Clin Infect Dis. 2006 Jan 15;42(2):211-5
pubmed: 16355331
BMC Infect Dis. 2009 Dec 04;9:196
pubmed: 19961583
Scand J Infect Dis. 2008;40(8):621-8
pubmed: 18979600
Pediatr Infect Dis J. 2014 Dec;33(12):1216-21
pubmed: 25037044
Emerg Infect Dis. 2010 Sep;16(9):1428-39
pubmed: 20735928
Vaccine. 2016 Sep 22;34(41):4850-4856
pubmed: 27595445
Lancet Glob Health. 2017 Jan;5(1):e51-e59
pubmed: 27955789
Clin Infect Dis. 1996 Jan;22(1):100-6
pubmed: 8824973